Development of new covered stent for obstructive colorectal cancer

[Background] We developed a new self-expanding covered stent (SECS), Kawasumi Jabara colonic stent developed to reduce injury of tumor and tumor growth in stent in the treatment of obstructive colorectal cancer (OCC). [Purpose] The purpose was to investigate the safety of Bridge to Surgery (BTS) using the SECS, compared to the self-expanding metallic stent (SEMS). [Patients and Methods] The 19 patients who underwent BTS for OCC (from descending colon to rectum) between September 2013 to January 2021 were enrolled in this study. Patient’s characteristics, short-term outcomes, and histopathological findings were evaluated. [Results] Among 19 patients, 7 patients used the SECS, and 12 in the SEMS. Compared to the SEMS group, the SECS group had no significant difference in gender, age, CROSS score, stent migration (2/7 vs. 1/12), preoperative perforation (0 vs. 0), cStageⅡ/Ⅲ/Ⅳ 0/3/4 vs.1/8/3), stent breakage (1/7  vs. 0/12), operation time (249 vs. 248min), blood loss (48 vs. 132ml), tumor growth in stent (0/7 vs. 12/12), and postoperative complications (1/7 vs. 3/12). In the SEMS group, tumor crushing due to stent that reached deeper than the muscular layer of the tumor was observed on 80% , whereas in the SECS group, 57%. [Conclusion] The short-term outcomes of BTS using the SECS for OCC might be feasible.